In six months, the number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases exceeded six million, with more than 360,000 deaths. The World Health Organization named the disease the coronavirus disease 2019 (COVID-19) and declared it a pandemic on 11 March 2020.1 Although the lung is the primary affected organ, the virus is neurovirulent and neuroinvasive with a growing recognition of neurological manifestations. The reported incidence of stroke in COVID-19 hospitalized patients is 0.9–2%,2,3 with an increased incidence in the young.4 More important than the increased incidence, is the poor outcome and high mortality rate, even with optimal treatment.5,6 A recent cross-sectional comparative study from New York identified a 7.5-fold higher rate of ischemic stroke in COVID-19 compared to influenza.3